Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is considered a promising investment due to their investigational drug assets that target Alzheimer's disease, a disease with no cure, prevention, or means of slowing progression. IGC-AD1 has shown significant potential in preclinical studies and is currently in a Phase 2B trial for agitation in dementia from Alzheimer's disease, while the company is also working on other drugs targeting Alzheimer's disease. Additionally, the company's recent fiscal year change from March to December and reported positive interim results add to the positive outlook for this stock in the long-term.

Bears say

IGC Pharma is facing significant risks to attain their share price target, such as balance sheet and liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials, and the need to gain regulatory approvals. Despite their recent positive interim results from their ongoing Phase 2 trial for IGC-AD1 as a treatment for agitation in dementia from Alzheimer's disease, the company has a long road ahead and will need additional positive data and progress to drive their stock price. With over 70% patient enrollment in their Phase 2 CALMA trial and potential billion dollars market potential, there may be high rewards for the risks, but the company's outlook remains negative for now.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.